The present authors report a 12-year-old Chinese child with generalized pustular psoriasis who was responded well to infliximab, but an adverse effect of herpes zoster occurred after the first infusion soon. The antiviral treatment was effective and no recurrence or flaring was observed after half-year of follow-up. This case reminds us to highlight the risk of viral infection during biological treatment on patients with psoriasis or autoimmune disease.

CONFLICT OF INTEREST

No conflict of interest disclosures.

REFERENCES

Adelzadeh, L., Jourabchi, N., & Wu, J. J. (2014). The risk of herpes zoster during biological therapy for psoriasis and other inflammatory conditions. Journal of the European Academy of Dermatology and Venereology, 28(7), 846–852.
10.1111/jdv.12307
CAS PubMed Web of Science® Google Scholar
Ali, T., Kaitha, S., Mahmood, S., Ftesi, A., Stone, J., & Bronze, M. S. (2013). Clinical use of anti-TNF therapy and increased risk of infections. Drug, Healthcare and Patient Safety, 5, 79–99.
10.2147/DHPS.S28801
PubMed Google Scholar
Dreiher, J., Kresch, F. S., Comaneshter, D., & Cohen, A. D. (2012). Risk of herpes zoster in patients with psoriasis treated with biologic drugs. Journal of the European Academy of Dermatology and Venereology, 26(9), 1127–1132.
10.1111/j.1468-3083.2011.04230.x
CAS PubMed Web of Science® Google Scholar
Fortina, A. B., Bardazzi, F., Berti, S., Carnevale, C., di Lernia, V., el Hachem, M., … Villani, A. (2017). Treatment of severe psoriasis in children: Recommendations of an Italian expert group. European Journal of Pediatrics, 176(10), 1339–1354.
10.1007/s00431-017-2985-x
CAS PubMed Web of Science® Google Scholar
Hambleton, S., & Gershon, A. A. (2005). Preventing varicella-zoster disease. Clinical Microbiology Reviews, 18(1), 70–80.
10.1128/CMR.18.1.70-80.2005
PubMed Web of Science® Google Scholar
Kunz, A. N., & Rajnik, M. (2011). Disseminated cutaneous varicella zoster virus infections during infliximab therapy for Crohn's disease: Case report of two pediatric patients at one institution. Clinical Pediatrics (Phila), 50(6), 559–561.
10.1177/0009922810380452
PubMed Web of Science® Google Scholar
Levandoski, K. A., Quesenberry, C. P., Tsai, A. L., & Asgari, M. M. (2018). Herpes zoster rates in a large cohort of patients with systemically treated psoriasis. JAMA Dermatology, 154((2)), 218–219.
10.1001/jamadermatol.2017.4840
PubMed Web of Science® Google Scholar
Mackey, A. C., Green, L., Liang, L. C., Dinndorf, P., & Avigan, M. (2007). Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition, 44(2), 265–267.
10.1097/MPG.0b013e31802f6424
PubMed Web of Science® Google Scholar
Nisar, M. K., & Ostor, A. J. (2013). TNF antagonists and shingles: Is vaccination advisable? Annals of the Rheumatic Diseases, 72(5), e1.
10.1136/annrheumdis-2013-203389
PubMed Web of Science® Google Scholar
Saikaly, S. K., & Mattes, M. (2016). Biologics and pediatric generalized pustular psoriasis: An emerging therapeutic trend. Cureus, 8(6), e652.
PubMed Web of Science® Google Scholar
Shalom, G., Zisman, D., Bitterman, H., Harman-Boehm, I., Greenberg-Dotan, S., Dreiher, J., … Cohen, A. D. (2015). Systemic therapy for psoriasis and the risk of herpes zoster: A 500,000 person-year study. JAMA Dermatology, 151(5), 533–538.
10.1001/jamadermatol.2014.4956
PubMed Web of Science® Google Scholar
Strangfeld, A., Listing, J., Herzer, P., Liebhaber, A., Rockwitz, K., Richter, C., & Zink, A. (2009). Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA, 301(7), 737–744.
10.1001/jama.2009.146
CAS PubMed Web of Science® Google Scholar
Tracey, D., Klareskog, L., Sasso, E. H., Salfeld, J. G., & Tak, P. P. (2008). Tumor necrosis factor antagonist mechanisms of action: A comprehensive review. Pharmacology & Therapeutics, 117(2), 244–279.
10.1016/j.pharmthera.2007.10.001
CAS PubMed Web of Science® Google Scholar
Tsang, V., Dvorakova, V., Enright, F., Murphy, M., & Gleeson, C. (2016). Successful use of infliximab as first line treatment for severe childhood generalized pustular psoriasis. Journal of the European Academy of Dermatology and Venereology, 30(11), e117–e119.
10.1111/jdv.13388
CAS PubMed Web of Science® Google Scholar
Wallis, R. S. (2008). Tumour necrosis factor antagonists: Structure, function, and tuberculosis risks. The Lancet Infectious Diseases, 8(10), 601–611.
10.1016/S1473-3099(08)70227-5
CAS PubMed Web of Science® Google Scholar
Wendling, D., Streit, G., Toussirot, E., & Prati, C. (2008). Herpes zoster in patients taking TNFalpha antagonists for chronic inflammatory joint disease. Joint, Bone, Spine, 75(5), 540–543.
10.1016/j.jbspin.2007.10.011
CAS PubMed Web of Science® Google Scholar
Whitley, R. J. (2008). Therapy of herpes virus infections in children. Advances in Experimental Medicine and Biology, 609, 216–232.
10.1007/978-0-387-73960-1_16
PubMed Web of Science® Google Scholar

Citing Literature

All articles

Development of herpes zoster during infliximab treatment for pediatric generalized pustular psoriasis: A case report

Abstract

CONFLICT OF INTEREST

REFERENCES

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Development of herpes zoster during infliximab treatment for pediatric generalized pustular psoriasis: A case report

Abstract

CONFLICT OF INTEREST

REFERENCES

Citing Literature

References

Related

Information